NCT07348120Completed
Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment
Efficacy and Safety of Millet Seed Extract in the Treatment of Telogen Effluvium in Female Patients: A Randomized, Double-Blind, Controlled Trial
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- Kasr El Aini Hospital
- Participants (registry)
- 60
- Start
- May 2025
- Primary completion
- February 2026
- Study completion
- March 2026
- Last registry update
- May 2026
- Countries
- Egypt
Conditions studied: Telogen Effluvium
Interventions: Millet Seed Extract group, Biotin group
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.